Author: owner     Published: 1 year ago 0 Replies

Sparsentan is a newly approved drug by the FDA for the treatment of high-risk patients with IgA Nephropathy. It has a unique mechanism of action as it blocks two receptors simultaneously:

  • Endothelin receptors, and 
  • Angiotensin receptors

The PROTECT trial demonstrated its efficacy in lowering proteinuria in patients with IgA nephropathy who were excreting proteins @ more than 1.5 gm/g of creatinine.

However, whether it protects the progression of IgA nephropathy to ESRD or advancing kidney disease is not yet clear.

Login to Reply

Money Back Guarantee
We return Money in 24 Hours

Secure online payment
We possess SSL / Secure Certificate

12/7 customer support
Well-trained & Supportive team

PMDC Verified Doctors
Authentic & updated information

Book Online and In-clinic appointment with your doctor. Consult via Video chat and get a prescription. Ask any question in the "Forum" section and get a detailed answer. Discuss your health issues.

Connect with us

Copyright @ 2024 - All Rights Reserved Reproduction of material from any pages without permission is strictly prohibited.